Abstract
Prostate cancer (PC) is the most common uro-oncological disease in the global population and still requires a more efficient laboratory diagnosis. Point mutations of oncogenes and tumor suppressor genes are the most frequent molecular genetic events in carcinogenesis. The mutations are responsible, to a great extent, for the clonal evolution of cancer and can be considered as primary candidate molecular markers of PC. Using next-generation sequencing to analyze the mutations in PC, the main molecular PC subtypes were identified, which depended on the presence of fusion genes and FOXA1, CHD1, and SPOP point mutations; other driver mutations responsible for the progression of PC subclones were also characterized. This review summarizes the data on early PC genetic markers (an mtDNA deletion, and TMPRSS2:ERG expression), as well as these somatic mutations at later stages of PC. Emphasis is placed on a switch in AR synthesis to a constitutively active variant and the point mutations that facilitate PC transition to a castration-refractory state that is resistant to new AR inhibitors. Based on the current whole-exome sequencing data, the frequencies and localizations of the somatic mutations that may provide new genetic diagnostic markers and drug targets are described.
Keywords: Oncogene, Somatic mutation, Clonal evolution, Prostate cancer, Diagnostics, Targeted therapy.
Current Genomics
Title:Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer
Volume: 18 Issue: 3
Author(s): Dmitry S. Mikhaylenko*, Gennady D. Efremov, Vladimir V. Strelnikov, Dmitry V. Zaletaev and Boris Y. Alekseev
Affiliation:
- Department of Pathology with Molecular Genetic Group, N. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Center, P.O. Box: 105425, Moscow,Russian Federation
Keywords: Oncogene, Somatic mutation, Clonal evolution, Prostate cancer, Diagnostics, Targeted therapy.
Abstract: Prostate cancer (PC) is the most common uro-oncological disease in the global population and still requires a more efficient laboratory diagnosis. Point mutations of oncogenes and tumor suppressor genes are the most frequent molecular genetic events in carcinogenesis. The mutations are responsible, to a great extent, for the clonal evolution of cancer and can be considered as primary candidate molecular markers of PC. Using next-generation sequencing to analyze the mutations in PC, the main molecular PC subtypes were identified, which depended on the presence of fusion genes and FOXA1, CHD1, and SPOP point mutations; other driver mutations responsible for the progression of PC subclones were also characterized. This review summarizes the data on early PC genetic markers (an mtDNA deletion, and TMPRSS2:ERG expression), as well as these somatic mutations at later stages of PC. Emphasis is placed on a switch in AR synthesis to a constitutively active variant and the point mutations that facilitate PC transition to a castration-refractory state that is resistant to new AR inhibitors. Based on the current whole-exome sequencing data, the frequencies and localizations of the somatic mutations that may provide new genetic diagnostic markers and drug targets are described.
Export Options
About this article
Cite this article as:
Mikhaylenko S. Dmitry*, Efremov D. Gennady, Strelnikov V. Vladimir, Zaletaev V. Dmitry and Alekseev Y. Boris, Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer, Current Genomics 2017; 18 (3) . https://dx.doi.org/10.2174/1389202917666161102095900
DOI https://dx.doi.org/10.2174/1389202917666161102095900 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors
Current Drug Metabolism Synthesis, Anticancer Activity on Prostate Cancer Cell Lines and Molecular Modeling Studies of Flurbiprofen-Thioether Derivatives as Potential Target of MetAP (Type II)
Medicinal Chemistry Fragment-based Discovery of Potential Anticancer Lead: Computational and in vitro Studies
Current Computer-Aided Drug Design Kisspeptin Mediated Signaling in Cancer
Current Topics in Medicinal Chemistry Colchicine: An Old Wine in a New Bottle?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology Is it Necessary to Calculate Young’s Modulus in AFM Nanoindentation Experiments Regarding Biological Samples?
Micro and Nanosystems Editorial [ Hot Topic: Wnt Signaling (Guest Editor: Rashna D. Balsara) ]
Current Drug Targets From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Current Pharmaceutical Design Targeting Mitochondria: A New Promising Approach for the Treatment of Liver Diseases
Current Medicinal Chemistry Two Panels of Steroid Receptor Luciferase Reporter Cell Lines for Compound Profiling
Combinatorial Chemistry & High Throughput Screening IGF-1 Gene Therapy as a Potentially Useful Therapy for Spontaneous Prolactinomas in Senile Rats
Current Gene Therapy Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients
Recent Patents on Anti-Infective Drug Discovery Raman Spectroscopy as a Novel Technology in Forensic Toxicological Analyses
Current Analytical Chemistry DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Thrombospondins as Anti-Angiogenic Therapeutic Agents
Current Pharmaceutical Design Decoding the Inter-Relationship between Sleep Disorders and Alzheimer’s Disease Pathogenesis
CNS & Neurological Disorders - Drug Targets Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry